» Articles » PMID: 21160909

Anaemia and Long Term Mortality in Heart Failure Patients: a Retrospective Study

Overview
Publisher Bentham Open
Date 2010 Dec 17
PMID 21160909
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Anaemia has been demonstrated as a risk factor in patients with heart failure over periods of a few years, but long term data are not available. We examined the long-term risk of anaemia in heart failure patients during 15 years of follow-up.

Methods: We evaluated survival data for 1518 patients with heart failure randomized into the Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) trial. The follow-up time was from 13 to 15 years. After 15 years 11.5% of the patients were still alive.

Results: Anaemia was present in 34% of the patients. 264 (17%) had mild, 152 (10%) had moderate and 98 (7%) had severe anaemia. Hazard ratio of death for patients with mild anaemia compared with patients with no anaemia was 1.27 (1.11-1.45, p<0.001), for moderate anaemia 1.48 (1.24-1.77, p<0.001) and for severe anaemia 1.82 (1.47-2.24, p<0.001), respectively. In multivariable analyses anaemia was still associated with increased mortality with hazard ratios of 1.19 (1.04-1.37, p=0.014) for mild anaemia, 1.23 (1.03-1.48, p=0.024) for moderate anaemia and 1.33 (1.07-1.66, p=0.010) for severe anaemia, respectively. In landmark analysis the increased mortality for mild anaemia was only significant during the first 2 years, while moderate anaemia remained significant for at least 5 years. There were too few patients left with severe anaemia after 5 years to evaluate the importance on mortality beyond this time.

Conclusion: Anaemia at the time of diagnosis of heart failure is an independent factor for mortality during the following years but loses its influence on mortality over time.

Citing Articles

Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients.

Winther S, Finer N, Sharma A, Torp-Pedersen C, Andersson C Int J Obes (Lond). 2013; 38(3):432-7.

PMID: 23774460 DOI: 10.1038/ijo.2013.111.


Differences in Clinical Presentation and Findings between Idiopathic Dilated and Ischaemic Cardiomyopathy in an Unselected Population of Heart Failure Patients.

Mantziari L, Ziakas A, Ventoulis I, Kamperidis V, Lilis L, Katsiki N Open Cardiovasc Med J. 2012; 6:98-105.

PMID: 23002403 PMC: 3447189. DOI: 10.2174/1874192401206010098.

References
1.
Van Veldhuisen D, Dickstein K, Cohen-Solal A, Lok D, Wasserman S, Baker N . Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J. 2007; 28(18):2208-16. DOI: 10.1093/eurheartj/ehm328. View

2.
Tang W, Tong W, Jain A, Francis G, Harris C, Young J . Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008; 51(5):569-76. DOI: 10.1016/j.jacc.2007.07.094. View

3.
Kober L, Torp-Pedersen C, Carlsen J, Videbaek R, Egeblad H . An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. Eur Heart J. 1994; 15(12):1616-20. DOI: 10.1093/oxfordjournals.eurheartj.a060443. View

4.
Van Veldhuisen D, McMurray J . Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail. 2007; 9(2):110-2. DOI: 10.1016/j.ejheart.2007.01.004. View

5.
. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality ON Dofetilide. Clin Cardiol. 1997; 20(8):704-10. PMC: 6656146. DOI: 10.1002/clc.4960200808. View